Background: Biomarkers of systemic inflammation predict non-AIDS events and overall mortality in virologically suppressed HIV-1-infected patients.
Introduction
Combination ART (cART) maintenance strategies have been proposed to reduce long-term drug toxicity, adverse effects and treatment costs in HIV-1-infected subjects. 1, 2 Within this context, the randomized ATLAS-M trial demonstrated the virological efficacy and safety of treatment simplification in virologically controlled HIV-1-infected patients to a dual regimen based on a boosted PI, i.e. atazanavir/ritonavir, plus lamivudine as a single NRTI, as compared with continuing a triple atazanavir/ritonavir-based therapy. 3 Consistently, this dual therapy demonstrated non-inferior efficacy with respect to standard triple therapy in the SALT trial. The impact of this simplification strategy on systemic inflammation has not yet been assessed.
Individuals with HIV-1 infection have elevated concentrations of soluble biomarkers of inflammation, monocyte activation and coagulation that decrease but do not normalize with cART, 5, 6 although the sources of this excess systemic inflammation are only partially known.
The plasma levels of these biomarkers have been found to predict severe non-AIDS events and overall mortality, even in patients on fully suppressive cART. [7] [8] [9] [10] [11] Thus, the quantification of these biomarkers may provide prognostic information in virologically suppressed patients.
Although in the ATLAS-M study there were no differences in plasma virological suppression between arms, dual therapy and triple therapy could impact the systemic inflammation differently through several mechanisms that have been hypothesized to be contributors to residual inflammation, including low-level HIV-1 replication in sanctuary sites (that may not be captured by HIV-1 levels in plasma), microbial translocation subsequent to HIV-1-related damage to the gastrointestinal tract, as well the potential direct effects of antiretrovirals on inflammatory pathways. 12 In this substudy, of the ATLAS-M trial we evaluated the impact of the simplification to atazanavir/ritonavir plus lamivudine dual therapy at 48 weeks on soluble markers of systemic inflammation. Factors associated with the levels of these biomarkers were also analysed.
Patients and methods

Study design
The ATLAS-M study is a multicentre, open-label, non-inferiority trial. It compared HIV-1-infected patients on cART with two NRTIs plus atazanavir/ritonavir, without previous virological failures, with HIV-1 RNA ,50 copies/mL for .3 months and CD4 .200 cells/mm 3 for .6 months, who were randomized either to switch to 300/100 mg of atazanavir/ritonavir plus 300 mg of lamivudine once daily or to continue the previous regimen.
In the current substudy, we included a subset of patients with available stored plasma specimens obtained at baseline and at 48 weeks. Changes from baseline to week 48 in systemic inflammation status were assessed by measuring plasma levels of two markers of inflammation, i.e. IL-6 and C-reactive protein (CRP), a marker of monocyte activation, soluble CD14 (sCD14) and a marker of pro-coagulation (D-dimer).
Biomarker assays
Blood samples were collected in tubes with EDTA; plasma was aliquoted and stored at #80 C until analysis. IL-6 and sCD14 were measured using Quantikine ELISA (nos D6050 and DC140; R&D Systems, Minneapolis, MN, USA) and CRP and D-dimer were measured using ELISA (ELH-CRP and ELH-DDIMER; Raybiotech Inc., Norcross, GA, USA), according to the manufacturers' instructions.
Samples were run without any dilution for IL-6 quantification, at 1:200 dilution for sCD14, at 1:20 000 dilution for CRP and at 250 000-fold dilution for D-dimer.
The lower limits of detection for IL-6, sCD14, CRP and D-dimer were 700 pg/L, 125 pg/mL, 34 pg/mL and 0.08 pg/mL, respectively. Markers were measured in duplicate and values averaged for analysis. The quantification of residual plasma viraemia (HIV-1 RNA ,50 copies/mL) and total HIV-1 DNA load (log 10 copies/10 6 leucocytes) was performed as previously described. 13 
Statistical analysis
Plasma levels of IL-6, CRP, sCD14 and D-dimer were log 10 -transformed to approximate a normal distribution. Comparisons between and within treatment arms were made using the parametric unpaired and paired sample t-tests, as appropriate. IL-6 levels below the assay detection limit (18% and 16% of samples tested at baseline and week 48, respectively) were set to the lower level of detection.
Residual viraemia was categorized as detectable (1-49 copies/mL) or undetectable (,1 copy/mL).
Linear regression analysis was used to assess the factors associated with the biomarker levels.
All analyses were performed using the IBM-SPSS Statistics version 22.0 (IBM Corp., Armonk, NY, USA).
Results
This substudy analysed 139 of 266 patients randomized in the ATLAS-M trial: 77.3% were male, mean age was 43 years (95% CI 42, 45), mean CD4 cell count was 660 (95% CI 615, 704), median time since HIV-1 diagnosis was 4.41 years (IQR 1.83, 9.58) and median time of cART exposure was 2.44 years (IQR 1.36, 5.00). As per the ATLAS-M trial inclusion criteria, all subjects had HIV-1 viral load ,50 copies/mL; however, 35.2% displayed an undetectable viraemia and 64.8% had detectable residual viraemia. The current subset included 70 patients who were randomized to the dual therapy arm and 69 patients randomized to maintain the triple therapy.
The patients included in the two arms were similar for the main characteristics (see Table 1 ) and did not differ from those of the entire cohort (data not shown).
The baseline levels of the biomarkers in the dual therapy arm and the triple therapy arm were comparable: IL-6, 3.28 (95% CI 3.19, 3.36) versus 3.28 (95% CI 3.17, 3.38) log 10 pg/L (P " 0.954); CRP, 6.48 (95% CI 6.33, 6.62) versus 6.50 (95% CI 6.39, 6.60) log 10 pg/mL (P " 0.812); sCD14, 6.08 (95% CI 6.06, 6.11) versus 6.11 (95% CI 6.07, 6.14) log 10 pg/mL (P " 0.241); and D-dimer, 5.50 (95% CI 5.45, 5.54) versus 5.48 (95% CI 5.43, 5.53) log 10 pg/mL (P " 0.553).
When we compared biomarker level changes between baseline and week 48 within each treatment arm, we found no significant changes from baseline (see Figure 1) .
No significant difference in log 10 change from baseline to week 48 was observed between arms (dual therapy versus triple therapy): IL-6 (pg/L), #0.030 (95% CI #0.098, !0.038) versus #0.016 (95% CI #0.108, !0.076) (P " 0.812); CRP (pg/mL), !0.022 (95% CI #0.074, !0.118) versus !0.027 (95% CI #0.076, !0.131) (P " 0.943); sCD14 (pg/mL), #0.016 (95% CI #0.042, !0.010) versus !0.019 (95% CI #0.015, !0.053) (P " 0.106); and D-dimer (pg/mL), #0.031 (95% CI #0.068, !0.006) versus !0.004 (95% CI #0.035, !0.043) (P " 0.198).
We have also performed subgroup analyses to explore the effect of removing specific drugs from the standard triple regimen. When patients were stratified according to the baseline regimen containing abacavir (100% combined with lamivudine) or tenofovir (98.3% combined with emtricitabine), we found no difference in change in any markers within or between dual and triple therapy arms (all P . 0.05). At week 48, the virological profile was comparable to that observed at baseline: most of the patients Belmonti et al. (Table S1 , available as Supplementary data at JAC Online).
Discussion
Despite complete virological suppression on cART, HIV-1-infected patients show a residual inflammatory response that has been related to long-term clinical consequences. [7] [8] [9] [10] [11] Therefore, additional information regarding the effects of ART strategies on inflammatory biomarkers is required.
Here, we showed that the changes at 1 year of inflammation, monocyte activation and coagulation marker levels in patients on atazanavir/ritonavir with two NRTIs were comparable after simplification to a dual therapy with atazanavir/ritonavir with lamivudine, as compared with continuation of the previous effective triple therapy. Inflammation markers in ATV/r plus 3TC dual therapy
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The levels of the biomarkers at baseline were similar to that previously reported in HIV-1-infected patients with HIV-1 RNA ,50 copies/mL. 6, 10 Moreover, we found minimal and no significant changes between baseline and week 48 within study arms. This is consistent with a previous longitudinal study that showed a plateau phase following an initial decrease in inflammatory biomarker levels within the first year after cART-induced HIV suppression. 6 Only few data exist regarding the effect of specific antiretrovirals on inflammation; most focus on differences between abacavir and tenofovir, given the association of abacavir with higher inflammation markers and with cardiovascular risks in some studies. 14 In our study, discontinuation of abacavir or tenofovir/ emtricitabine did not differentially impact systemic inflammation in the simplification strategy. However, it should be noted that the low frequency of patients who were receiving the abacavircontaining regimen in each arm limited the power of our analysis. Our results highlight differences with respect to what has been observed in PI-based monotherapy studies. In fact, in a previous cross-sectional analysis, patients who successfully simplified to monotherapy with a boosted PI showed a higher level of markers of inflammation and monocyte activation than those on a PI-based three-drug regimen. Moreover, in this study a higher level of inflammation was related to higher residual viraemia. 15 By contrast, consistent with other studies, here we failed to find a relationship between detectable residual viraemia and higher levels of the inflammatory biomarkers. 16, 17 In addition, we found no relationship between HIV-1 DNA levels and markers of inflammation, which is concordant with another report. 18 Taken together these observations suggest that in patients on suppressive cART a residual inflammatory response may not be directly related to the size of the viral reservoir and the presence of residual viraemia. On the other hand, residual inflammatory status may be related to multifactorial mechanisms beyond the direct effects of HIV replication; however, the sources of this excess inflammation are only partially known.
In our study, we found an association between the baseline levels of IL-6 and CRP with a history of cancer, showing that residual inflammation may partially represent immunological processes that continue as a consequence of previous damage.
In this subset, we found no relationship between the levels of plasma lipids and markers of systemic inflammation. This observation supports previous cART-switch randomized trials, which showed that changes in inflammatory markers were independent of lipid changes 19, 20 and suggests that the association between plasma lipids and inflammatory biomarkers usually seen in the general population 21 cannot be fully applied in the case of HIV-1-infected subjects in whom lipid levels may be influenced by other factors, including cART.
Our study is limited by its relatively short follow-up period. Nevertheless, the strength of the randomization in treatment allocation rules out the effects of traditional confounders such as concomitant morbidity on systemic inflammation.
In conclusion, this ATLAS-M substudy shows that in virologically controlled patients, simplification to atazanavir/ritonavir plus lamivudine as a maintenance therapy has the same impact on systemic inflammation biomarkers as continued atazanavir/ritonavir with two NRTIs; thus, it adds further evidence in support of the safety of this approach.
The long-term clinical consequences of these findings on dual maintenance cART require further evaluation.
